SCHEMBL6793526

SCHEMBL6793526

CC1(C(O)c2ccc(-c3ccc(C(=O)O)cc3)cc2)NC(=O)NC1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
MMP2 P08253 5/20 0.39
MMP9 P14780 5/20 0.39
MMP8 P22894 5/20 0.39
PDE5A O76074 1/20 0.39
PDE1A P54750 1/20 0.39
PDE1B Q01064 1/20 0.39
PDE4D Q08499 1/20 0.39
PDE7A Q13946 1/20 0.39
PDE1C Q14123 1/20 0.39
PDE3A Q14432 1/20 0.39
RXRA P19793 3/20 0.38
RXRB P28702 2/20 0.38
RXRG P48443 1/20 0.38
BCL2L1 Q07817 1/20 0.37
BAD Q92934 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6789361 0.87 MMP2 (0.41) MMP2MMP9MMP8
SCHEMBL6791227 0.87 MMP2 (0.41) MMP2MMP9MMP8
SCHEMBL6791153 0.87 MMP2 (0.41) MMP2MMP9MMP8
SCHEMBL6798425 0.82 CYP17A1 (0.37) PDE5APDE1APDE1BPDE4DPDE7A
SCHEMBL6840968 0.81 HPGD (0.47) PDE5APDE1APDE1BPDE4DPDE7A
SCHEMBL27602477 0.81 RXRA (0.41) CA12CA1CA2CA9MMP2
SCHEMBL6792387 0.81 MMP2 (0.45) MMP2MMP9MMP8
SCHEMBL6791811 0.81 TYR (0.38) MMP2MMP9GRIA4
SCHEMBL6793293 0.80 NPC1 (0.48)
SCHEMBL6944232 0.80 ROCK2 (0.49) CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
US-20040110809-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-06-10 US disclosed
EP-1370536-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
EP-1370538-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074752-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed
WO-2002074750-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110809-A1 Metalloproteinase inhibitors MMP9, MMP2, MMP3 CA12 245/4885CA1 362/4885CA2 341/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 CA12 415/4885CA1 134/4885CA2 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.